EEF1A1P14: A Potential Drug Target and Biomarker in Eukaryotes

Target Name: EEF1A1P14

NCBI ID: G647167

EEF1A1P14

Other Name(s): eukaryotic translation elongation factor 1 alpha 1 pseudogene 14 | Eukaryotic translation elongation factor 1 alpha 1 pseudogene 14 | EEF1AL12

EEF1A1P14: A Potential Drug Target and Biomarker in Eukaryotes

Introduction

The eukaryotic translation elongation factor 1 alpha 1 pseudogene 14 (EEF1A1P14) is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. It is a key regulator of the translation of membrane proteins, which are involved in various cellular processes, including cell signaling, structure, and homeostasis. EEF1A1P14 functions as a negative regulator of the translation of its target proteins by binding to specific AUGs (amino acids that are specific for the translation machinery) and preventing their translation into cytoplasmic polyproteins.

Recent studies have identified EEF1A1P14 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions in these diseases have been studied extensively, and several studies have demonstrated its potential as a drug target. In this article, we will discuss the current state of research on EEF1A1P14 as a drug target and biomarker and highlight its potential as a potential therapeutic approach.

Potential Drug Target

EEF1A1P14 has been identified as a potential drug target due to its involvement in the regulation of protein translation, which is a critical process for the development and progression of many diseases. Many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders, are characterized by the overproduction or underproduction of specific proteins. This overproduction or underproduction of proteins can lead to the formation of aggregates or the disruption of cellular homeostasis, leading to the development of diseases.

Several studies have demonstrated that EEF1A1P14 plays a critical role in the regulation of protein translation in various diseases. For example, studies have shown that EEF1A1P14 can inhibit the translation of cancer-related proteins, including and tyrosine kinase receptor (EGFR) proteins, which are involved in the development of cancer. Similarly, EEF1A1P14 has also been shown to regulate the translation of neurodegenerative diseases-related proteins, including dopamine receptor (DRD2) genes, which are involved in the development of neurodegenerative diseases.

Biomarker

EEF1A1P14 has also been identified as a potential biomarker for various diseases due to its expression levels. Studies have shown that the expression of EEF1A1P14 is significantly increased in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This increase in EEF1A1P14 expression levels can be used as a diagnostic or predictive marker for these diseases.

The potential use of EEF1A1P14 as a biomarker has been demonstrated in several studies. For example, studies have shown that the expression of EEF1A1P14 is significantly increased in various types of cancer, including breast, ovarian, and colorectal cancer. Similarly, studies have also shown that EEF1A1P14 is significantly increased in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its use as a biomarker, EEF1A1P14 has also been shown to be involved in the development of autoimmune disorders. Studies have shown that EEF1A1P14 is involved in the regulation of the development and progression of autoimmune disorders, including rheumatoid arthritis (RA) and multiple sclerosis (MS).

Conclusion

EEF1A1P14 has been identified as a potential drug target and biomarker in eukaryotes due to its involvement in the regulation of protein translation and its expression levels. Its functions in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders have been studied extensively. As a As a result of these studies, EEF1A1P14 has emerged as a promising target for the development of new therapeutic approaches for these diseases. Further research is needed to

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 14

The "EEF1A1P14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets